Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43

Benzinga · 2d ago
Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and lowers the price target from $46 to $43.